Anti-Human CD20 Reference Antibody (DXL625, RUO) (HY257336)

Name: Anti-Human CD20 Reference Antibody (DXL625, RUO)
Brand: abinScience
SKU: HY257336
Price: 370 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HY257336
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	DXL625
Biological activity	DXL625 (1-25 ug/mL; 24 h, 48 h) induces dose-dependent and time-dependent reductions in ATP content in Ramos Burkitt’s lymphoma cells, with greater potency than Rituxan at all tested concentrations (1, 5, 10, 25 ug/mL) after 24 and 48 hours of treatment [1]. DXL625 (1-25 ug/mL; 24 h) induces dose-dependent caspase-mediated apoptosis in Ramos Burkitt’s lymphoma cells, with 30.0% of cells undergoing apoptosis at the highest tested concentration (25 ug/mL) after 24 hours of treatment [1]. DXL625 (10 ug/mL; 24 h) induces caspase-mediated apoptosis in Ramos Burkitt’s lymphoma cells, with 24.2% of cells testing positive for activated caspases after 24 hours of treatment with 10 ug/mL DXL625 [1]. DXL625 (10 ug/mL; 2 h) induces complement-dependent cytotoxicity in Ramos Burkitt’s lymphoma cells, resulting in 56.5% cell death after 2 hours of treatment with 10 ug/mL DXL625 in the presence of 5% (v/v) rabbit complement sera [1]. DXL625 (10 ug/mL; 2 h) retains complement-dependent cytotoxicity activity against primary CD19 + B-lymphocytes from healthy donor peripheral blood lymphocytes, reducing the CD19 + population to 3.1% after 2 hours of treatment with 10 ug/mL DXL625 in the presence of 5% (v/v) rabbit complement sera [1]. DXL625 (10 ug/mL; 24 h) induces enhanced NK cell-mediated antibody-dependent cellular cytotoxicity in Ramos Burkitt’s lymphoma cells, reducing normalized cell viability to 0.56 after 24 hours of treatment with 10 ug/mL DXL625 at a 6:1 effector-to-target ratio [1]. . Reduced cellular ATP content by 36.5%, 46.3%, 48.3%, and 48.5% at concentrations of 1, 5, 10, and 25 ug/mL, respectively, after 48 hours compared to vehicle-treated cells.
Expression system	Mammalian cells
Clonality	Monoclonal
Target	B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P11836
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	DXL625
Background	B-lymphocyte antigen CD20 (MS4A1) is a ~33 kDa protein. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. CD20 is the therapeutic target of rituximab (MabThera) and obinutuzumab (Gazyva). 1. Li, H. et al. (2003) The Journal of biological chemistry 278, 42427-34. PMID: 12920111 2. Tedder, TF. et al. (1985) Journal of immunology (Baltimore, Md. : 1950) 135, 973-9. PMID: 3925015 3. Bubien, JK. et al. (1993) The Journal of cell biology 121, 1121-32. PMID: 7684739 4. Polyak, MJ. et al. (2008) The Journal of biological chemistry 283, 18545-52. PMID: 18474602
References	1. Bingaman MG, et al. The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis. Anticancer Drugs. 2010;21(5):532-542. [HY257336]
Note	For research use only. Not suitable for clinical or therapeutic use.